{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:53:10Z","timestamp":1773154390906,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41440-020-0452-y","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:18:26Z","timestamp":1589264306000},"page":"726-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Does cilnidipine, a dual L- and N-type Ca2+ blocker, shows promise in drug repositioning approaches?"],"prefix":"10.1038","volume":"43","author":[{"given":"Aya","family":"Shiraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41440-019-0391-7","volume":"43","author":"H Minato","year":"2020","unstructured":"Minato H, Hisatome I, Kurata Y, Notsu T, Nakasone N, Ninomiya H, et al. Pretreatment with cilnidipine attenuates hypoxia\/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening. Hypertens Res. 2020;43:380\u20138.","journal-title":"Hypertens Res"},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1161\/01.RES.78.6.998","volume":"78","author":"X Han","year":"1996","unstructured":"Han X, Kobzik L, Balligand JL, Kelly RA, Smith TW. Nitric oxide synthase (NOS3)-mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells. Circ Res. 1996;78:998\u20131008.","journal-title":"Circ Res"},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ceca.2015.08.006","volume":"58","author":"L Borysova","year":"2015","unstructured":"Borysova L, Burdyga T. Evidence that NO\/cGMP\/PKG signalling cascade mediates endothelium dependent inhibition of IP3R mediated Ca2+ oscillations in myocytes and pericytes of ureteric microvascular network in situ. Cell Calcium. 2015;58:535\u201340.","journal-title":"Cell Calcium"},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cardiores.2006.02.020","volume":"70","author":"Y Abdallah","year":"2006","unstructured":"Abdallah Y, Gkatzoflia A, Gligorievski D, Kasseckert S, Euler G, Schl\u00fcter KD, et al. Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res. 2006;70:346\u201353.","journal-title":"Cardiovasc Res"},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCULATIONAHA.113.006641","volume":"129","author":"N Voigt","year":"2014","unstructured":"Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129:145\u201356.","journal-title":"Circulation"},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tcm.2014.12.015","volume":"25","author":"J Jalife","year":"2015","unstructured":"Jalife J, Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015;25:475\u201384.","journal-title":"Trends Cardiovasc Med"},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCRESAHA.111.243956","volume":"110","author":"PD Swaminathan","year":"2012","unstructured":"Swaminathan PD, Purohit A, Hund TJ, Anderson ME. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res. 2012;110:1661\u201377.","journal-title":"Circ Res"},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.hrthm.2019.10.016","volume":"17","author":"A Greer-Short","year":"2020","unstructured":"Greer-Short A, Musa H, Alsina KM, Ni L, Word TA, Reynolds JO, et al. Calmodulin kinase II regulates atrial myocyte late sodium current, calcium handling, and atrial arrhythmia. Heart Rhythm. 2020;17:503\u201311.","journal-title":"Heart Rhythm"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/eurheartj\/ehs079","volume":"33","author":"S Nattel","year":"2012","unstructured":"Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33:1870\u20137.","journal-title":"Eur Heart J"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/cvr\/cvz136","volume":"115","author":"K Tajiri","year":"2019","unstructured":"Tajiri K, Guichard JB, Qi X, Xiong N, Tardif JC, Costa AD, et al. An sN-\/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. Cardiovasc Res. 2019;115:1975\u201385.","journal-title":"Cardiovasc Res"},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"eaat5185","DOI":"10.1126\/scisignal.aat5185","volume":"11","author":"A Nishimura","year":"2018","unstructured":"Nishimura A, Shimauchi T, Tanaka T, Shimoda K, Toyama T, Kitajima N, et al. Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission-associated myocardial senescence. Sci Signal. 2018;11:eaat5185.","journal-title":"Sci Signal"},{"key":"452_CR12","doi-asserted-by":"crossref","unstructured":"Nishimura A, Shimoda K, Tanaka T, Toyama T, Nishiyama K, Shinkai Y, et al. Depolysulfidation of Drp1 induced by low-dose methylmercury exposure increases cardiac vulnerability to hemodynamic overload. Sci Signal. 2019;12.","DOI":"10.1126\/scisignal.aaw1920"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-0452-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-0452-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-0452-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:24:29Z","timestamp":1684617869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-0452-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-0452-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KN has received grants from Mitsubishi Tanabe; personal fees from MSD, Astellas, Amgen Astellas, AstraZeneca, Eli Lilly, Otsuka, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Bayer, Pfizer, Ono, and Mitsubishi Tanabe; grants from Asahi Kasei, Astellas, Mitsubishi Tanabe, Teijin, Terumo, Boehringer Ingelheim, and Bayer; and scholarships from Bayer, Daiichi Sankyo, Teijin, Astellas, Takeda, and Bristol-Myers Squibb. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}